Table 1.
Demographics, baseline characteristics, treatment and outcomes of patients with co-infection of SARS-CoV-2 and HIV.
| Characteristics | Patients (n = 20) | Characteristics | Patients (n = 20) |
|---|---|---|---|
| Age, median (IQR), y | 46.5 (39.3-50.5) | Sore throat | 1 (5%) |
| Sex | Diarrhea | 1 (5%) | |
| Male | 5 (25%) | Abdominal pain | 1 (5%) |
| Female | 15 (75%) | Dizziness | 1 (5%) |
| Exposure History | 16 (76%) | Anorexia | 1 (5%) |
| Exposure to Huanan Seafood market | 1 (5%) | Clinical classification | |
| Exposure to Infected Patients | 15 (75%) | Non-severe | 17 (85%) |
| Unknown Exposure | 4 (20%) | Severe | 3 (15%) |
| Comorbidities | 15 (75%) | ART before SARS-CoV-2 infection | 12 (60%) |
| Hepatitis C | 8 (40%) | NRTIs | 12/12 (100%) |
| Syphilis | 4 (20%) | Non-NRTIs | 6/12 (50%) |
| Other chronic liver disease | 3 (15%) | PI | 8/12 (67%) |
| Hypertension | 3 (15%) | Treatment during hospitalization | |
| CHD | 1 (5%) | Antiviral | 19 (95%) |
| Diabetes | 1 (5%) | ART | 19 (95%) |
| Hepatitis B | 1 (5%) | Corticosteroids | 1 (5%) |
| COPD | 1 (5%) | Chinese herbals | 4 (20%) |
| Psychosis | 1 (5%) | Oxygen therapy | 3 (15%) |
| Signs and symptoms | Immunoglobulin | 2 (10%) | |
| Cough | 13 (65%) | ICU admission | 0 |
| Fever | 9 (45%) | Outcome | |
| Expectoration | 5 (25%) | Discharged | 19 (95%) |
| Shortness of breath | 4 (20%) | Died | 1 (5%) |
| Fatigue | 2 (10%) |
Abbreviations: IQR, interquartile range; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; NRTI, snucleoside reverse transcriptase inhibitors; Non-NRTIs, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; ART, antiretroviral therapy; ICU, intensive care unit.